Insulet Corporation
$ 145.76
1.56%
18 Jun - close price
- Market Cap 9,940,866,000 USD
- Current Price $ 145.76
- High / Low $ 146.22 / 142.10
- Stock P/E 33.53
- Book Value 18.81
- EPS 4.28
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.10 %
- ROE 0.23 %
- 52 Week High 354.88
- 52 Week Low 140.63
About
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts.
Analyst Target Price
$242.43
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-18 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-20 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-22 | 2023-11-02 | 2023-08-08 |
| Reported EPS | 1.3 | 1.55 | 1.24 | 1.17 | 1.02 | 1.15 | 0.9 | 0.55 | 0.73 | 1.4 | 0.71 | 0.38 |
| Estimated EPS | 1.16 | 1.48 | 1.15 | 0.93 | 0.79 | 1.021 | 0.76 | 0.56 | 0.4 | 0.66 | 0.41 | 0.26 |
| Surprise | 0.14 | 0.07 | 0.09 | 0.24 | 0.23 | 0.129 | 0.14 | -0.01 | 0.33 | 0.74 | 0.3 | 0.12 |
| Surprise Percentage | 12.069% | 4.7297% | 7.8261% | 25.8065% | 29.1139% | 12.6347% | 18.4211% | -1.7857% | 82.5% | 112.1212% | 73.1707% | 46.1538% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.37 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PODD
2026-06-18 23:38:35
Insulet Corp. (PODD) stock rose 1.56% to $145.76, outperforming the broader market on a strong trading day where the S&P 500 and Dow Jones Industrial Average also saw gains. This positive movement ended a three-day losing streak for the company's shares.
2026-06-17 22:08:21
Insulet Corp (PODD) has an earnings forecast score of 8.50, ranking 27th in the Healthcare Equipment & Supplies industry, with an average price target of $380.00. Analysts largely recommend a "Buy" for the stock, with 26 out of 28 analysts giving a positive rating. The company's expected revenue for the next quarter is $787.45 million, and its estimated EPS for the upcoming quarter is $1.45.
2026-06-17 17:15:00
Insulet Corp. (PODD) stock fell 2.82% to $143.52 on Wednesday, underperforming the broader market as the S&P 500 Index and Dow Jones Industrial Average also declined. This marked the third consecutive day of losses for Insulet, whose stock performance was weaker than its competitors.
2026-06-17 09:38:29
Insulet Corp. (PODD) stock performed worse than its competitors on Wednesday, falling 2.05% to $161.40. This decline occurred despite a positive day for the broader stock market, with the S&P 500 rising 1.17%.
2026-06-17 09:08:44
This article provides an AI-driven analysis of Insulet Corporation (NASDAQ: PODD), highlighting a near-term weak sentiment that may signal a resumption of long-term weakness. It identifies a strong risk-reward setup targeting a 25.7% gain against 0.3% risk. The analysis also details three institutional trading strategies tailored for different risk profiles: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis.
2026-06-16 13:37:03
Abbott's continuous glucose monitoring (CGM) business, driven by its Libre portfolio, saw moderated growth in Q1 2026 due to an international tender renewal delay and tough comparisons. Despite this, management expects double-digit growth to return in Q2, supported by strong market fundamentals, cost advantages, and continuous innovation, including new products like Libre Duo and AI-powered Libre Assist. Competitors DexCom and Insulet are also advancing their CGM technologies, with DexCom showing significant clinical benefits for various Type 2 non-insulin using patients and Insulet developing future tubeless Automated Insulin Delivery systems.
